Integrin-mediated drug targeting

US7220824B1 · kind B1 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Jorg Baumgarten · Wuppertal, DE
• Ulf Bruggemeier · Leichlingen, DE
• Markus Albers · Leverkusen, DE
• Andreas Schoop · Overath, DE
• Thomas-J. Schulze · Thousand Oaks, US

Key dates

• Filing date: Aug 28, 2000
• Grant date: May 22, 2007
• Expiry date: Sep 12, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/22
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and αvβ3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.